Insulin lispro
Also known as: Admelog, B28 lispro, B28Lys,B29Pro human insulin, Humalog, Insulin lispro, Lispro insulin, LY275585, Lyumjev
Source Insulin lispro at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Insulin lispro is a rapid‑acting insulin analog used to control post‑prandial hyperglycemia in patients with type 1 or type 2 diabetes mellitus.
Mechanism of Action
Binds the insulin receptor, activating downstream signaling that promotes glucose uptake and inhibits hepatic glucose production.
Routes of Administration
Goals & Uses
- Gestational diabetes requiring insulin therapyObstetric Glycemic ManagementModerate
- Prandial glycemic control in type 1 diabetesGlycemic ManagementHigh
- Management of diabetic ketoacidosis (IV use)Acute Diabetes ManagementModerate
- Glycemic controlDiabetesHigh
- Continuous subcutaneous insulin infusion (CSII)Delivery OptimizationHigh
- Prandial glycemic control in type 2 diabetesGlycemic ManagementHigh
Contraindications
- Hypersensitivity to insulin lispro or its excipientsImmunologicModerate
- Hypersensitivity to insulin lispro or excipientsImmunologicHigh
- Hypoglycemia (active episode)MetabolicHigh
- HypoglycemiaMetabolicHigh
Adverse Effects
- HypokalemiaElectrolyteUncommon
- HypoglycemiaMetabolicCommonAbnormally low blood glucose
- Peripheral edemaFluid BalanceUncommonSwelling of the arms or legs
- Injection site reactionsLocalUncommon
- Injection site reactions (lipohypertrophy, lipoatrophy)Local / DermatologicCommon
- Anaphylaxis/systemic allergic reactionsImmunologicRare
- Weight gainMetabolicCommonIncrease in body weight
Drug Interactions
- Thiazolidinediones (e.g., pioglitazone)Moderate
- Beta‑blockersModerate
- Salicylates (high-dose aspirin)Low
- Beta-blockersModerate
- AlcoholModerate
- CorticosteroidsModerate
- ACE inhibitorsLow
Population Constraints
- PregnancyReproductive SafetyRelative
- Hepatic impairmentOrgan FunctionRelative
- Renal impairmentOrgan ImpairmentRelative
- Pediatric patientsAgeRelative
- Elderly patientsAgeRelative
- Pregnant womenReproductiveRelative
- Pediatric patients (<2 years)AgeRelative
Regulatory Status
- European UnionApprovedApproved: type 1 diabetes mellitus, type 2 diabetes mellitusEMA approval; same brand names.
- United StatesApprovedApproved: type 1 diabetes mellitus, type 2 diabetes mellitusFDA approved 1996; marketed as Humalog.
- United KingdomApprovedApproved: type 1 diabetes mellitus, type 2 diabetes mellitusMHRA approval; available as Humalog.
Approved in the US (FDA), EU (EMA), and UK (MHRA) as a rapid‑acting mealtime insulin. Marketed under the brand name Humalog.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Insulin lispro?
Insulin lispro is a rapid‑acting insulin analog used to control post‑prandial hyperglycemia in patients with type 1 or type 2 diabetes mellitus.
What is Insulin lispro used for?
Insulin lispro is educationally associated with: Gestational diabetes requiring insulin therapy, Prandial glycemic control in type 1 diabetes, Management of diabetic ketoacidosis (IV use), Glycemic control, Continuous subcutaneous insulin infusion (CSII), Prandial glycemic control in type 2 diabetes. Educational only — not medical advice.
How is Insulin lispro administered?
Recorded routes of administration: Continuous Subcutaneous Infusion (pump), Intravenous, Subcutaneous.
What are the potential side effects of Insulin lispro?
Reported adverse effects include: Hypokalemia, Hypoglycemia, Peripheral edema, Injection site reactions, Injection site reactions (lipohypertrophy, lipoatrophy), Anaphylaxis/systemic allergic reactions, Weight gain. This list is not exhaustive — consult a qualified clinician.
Who should avoid Insulin lispro?
Recorded contraindications: Hypersensitivity to insulin lispro or its excipients, Hypersensitivity to insulin lispro or excipients, Hypoglycemia (active episode), Hypoglycemia. Consult a qualified clinician before use.